Report : Asia Pacific Spirometer Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Handheld Spirometers, Table-top Spirometers, and Desktop Spirometers), Technology (Volume, Flow, and Peak Flow), and Application (Asthma, Chronic Obstructive Pulmonary Disease, Cystic Fibrosis, and Others) 

At 12.0% CAGR, the Asia Pacific Spirometer Market is speculated to be worth US$ 414.09 million by 2028, says Business Market Insights

According to Business Market Insights’ research, the Asia Pacific spirometer market was valued at US$ 210.00 million in 2022 and is expected to reach US$ 414.09 million by 2028, registering an annual growth rate of 12.0% from 2022 to 2028. The increasing preference of home care products and increasing government initiatives are the critical factors attributed to the market expansion.

The market for pulmonary devices is growing owing to the higher adoption of home care products. The high growth potential in emerging markets and the development of miniaturized devices are among the crucial factors anticipated to provide growth opportunities to players operating in the spirometer home healthcare market. Due to rising healthcare costs, many patients suffering from chronic respiratory diseases prefer to undergo treatments in-home care settings. In addition, lung transplantation has become the ultimate therapeutic option for some patients with advanced lung disease. Transplantation outcomes has been improved with advances in operative techniques; however, optimal management of infection and organ rejection remains a problem, because the complications may be undetectable at early phases through routine clinical evaluation. In such cases, home spirometry serves as a useful instrument that can measure lung function, help monitor the progress post lung transplantation, and aid in the early detection of allograft dysfunction. Home spirometry offers advantages over clinic spirometry as it provides increased convenience for patients and more frequent lung function measurements, enabling early disease progression detection. Moreover, home spirometers are widely used to provide easy access to more detailed information regarding lung function. Spirometry is also used before lung cancer surgery to predict how well a patient will tolerate the operation and manage it once a portion or lobe of a lung is removed. In addition, one such spirometer is alveoair, a personal spirometer designed for asthma, COPD, and cystic fibrosis patients to help quantify their lung health. It enables patients to monitor their disease at home to help avoid attacks and unnecessary hospital visits. Alveoair is a clinically trialed spirometer that has completed its clinical trial in January 2021 and provides results at par with a hospital-grade spirometer. Furthermore, home monitoring of physiological variables has become progressively more practical with the miniaturization and falling costs of devices and consequent improvements in wireless electronic connectivity. Additionally, within respiratory medicine, home disease monitoring in the form of peak flow measurement is already a feature of asthma self-management. In lung transplantation recipients, daily surveillance spirometry is used to detect acute rejection episodes and has been preferred by many patients. By using home spirometry and daily check of its result, healthcare givers can have a close observation of the patients and help them to manage their health at home. Thus, the increasing preference for home care products is driving the spirometer market growth.

On the contrary, unfavorable reimbursement scenario hurdles the growth of Asia Pacific spirometer market.

Based on type, the Asia Pacific spirometer market is segmented into handheld spirometers, table-top spirometers, and desktop spirometers. The table-top spirometers segment held 43.5% market share in 2022, amassing US$ 91.45 million. It is projected to garner US$ 175.63 million by 2028 to expand at 11.5% CAGR during 2022–2028.

The Asia Pacific spirometer market, by technology, is segmented into volume, flow, and peak flow. The flow segment held 48.4% market share in 2022, amassing US$ 101.74 million. It is projected to garner US$ 203.39 million by 2028 to expand at 12.2% CAGR during 2022–2028.

The Asia Pacific spirometer market, by application is segmented into asthma, chronic obstructive pulmonary disease, cystic fibrosis, and others. With 39.8% share of the domain, the chronic obstructive pulmonary disease segment dominated the market in 2022. It accrued US$ 83.49 million in 2022 and is estimated to generate US$ 166.37 million by 2028 to grow at a CAGR of 12.2% over the forecast period.

Based on country, the Asia Pacific spirometer market is categorized into China, Japan, India, South Korea, Australia, and the rest of Asia Pacific. Our regional analysis states that China captured 25.7% market share in 2022. It was assessed at US$ 54.07 million in 2022 and is likely to hit US$ 110.31 million by 2028, exhibiting a CAGR of 12.6% during the forecast period.

Key players dominating the Asia Pacific spirometer market are Baxter International Inc.; COSMED Srl; Henry Schein, Inc.; ICU Medical Inc.; Teleflex Incorporated; and VYAIRE MEDICAL, INC among others.

Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id:

Download Free PDF Brochure